Lenvatinib and Pembrolizumab in Head and Neck Cancer: A Gain or a Paradox?
In this article
Results of the LEAP-010 study: adding a targeted agent in PD-L1-positive advanced head and neck carcinoma improved tumor control but offered no survival advantage.
Historical context and the current treatment algorithm
Until a decade ago, treatment for metastatic head and neck cancer was limited to the "EXTREME" regimen (Platinum + 5-FU + Cetuximab). Today, treatment decisions are shaped entirely by **PD-L1 status**. Here is the current clinical approach:
Platinum + 5-FU + Cetuximab
(EXTREME Regimen)
Standard Care:
Pembrolizumab (Alone)
OR
Pembrolizumab + Chemotherapy
Pembro + Lenvatinib
(No OS Advantage Achieved)
LEAP-010: Study design and patient population
This Phase III randomized, double-blind study, conducted at 140 centers worldwide, included 511 patients who were not considered curable with local treatments such as surgery or radiotherapy.
256 patients received 20 mg of oral lenvatinib daily and 200 mg of intravenous pembrolizumab every 3 weeks.
255 patients were followed with placebo and standard pembrolizumab treatment every 3 weeks.
Clinical results: tumors shrank, but life was not prolonged
Although the study's initial interim analyses generated great excitement, the final survival data did not meet expectations. Here are the comparative LEAP-010 data:
| Clinical Parameter | Lenvatinib + Pembrolizumab | Placebo + Pembrolizumab | Result |
|---|---|---|---|
| Objective Response Rate (ORR) | %46.1 | %25.4 | Combination superior |
| Median PFS (Progression-Free Time) | 6.2 Months | 2.8 Months | 36% reduction in risk |
| Median OS (Overall Survival) | 15.0 Months | 17.9 Months | No significant difference (HR 1.15) |
| Grade 3-4 Adverse Effects | %66.9 | %38.3 | High toxicity |
Why Was Survival Not Prolonged?
The researchers attribute this paradox to two reasons: first, 44.7% of patients in the placebo arm had the opportunity to receive more treatment in the next line (crossover effect). Second, and more critically, the number of patients who discontinued treatment because of adverse effects was very high in the lenvatinib group. High toxicity may have masked or exhausted the progression-free survival advantage in terms of overall survival.
Current clinical practice: has the standard changed?
The clear message of LEAP-010 is this:In patients with metastatic head and neck cancer and PD-L1 CPS ≥ 1, the gold standard for first-line treatment remains pembrolizumab alone or the combination of pembrolizumab + chemotherapy.
Adding lenvatinib may be considered only in selected cases requiring a very rapid reduction in tumor burden (with a symptomatic mass); however, the fact that this approach does not prolong life and carries a heavy burden of adverse effects must be accurately communicated to the patient.
DROZDOGAN Academy Commentary
Our greatest misconception on the journey toward healing from cancer is believing that "more powerful weapons" will always yield better results. The LEAP-010 study whispers this to us: biological restoration means not only striking the tumor, but also preserving the body's tolerance of this treatment.
Precise guidance means not only prescribing a medicine to the patient but also anticipating in time what that medicine will take away from their quality of life. In a disease group with a heavy physical and psychological burden, such as head and neck cancer, a regimen that increases toxicity without prolonging survival may not be a "precise" choice, however much it shrinks the tumor. Healing means respecting nature's balance and combining the data with the patient's peace of mind.
Scientific References and Further Reading
- 1. Licitra L, et al. "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for R/M HNSCC: Phase III LEAP-010 Study." Journal of Clinical Oncology. March 12, 2026. doi:10.1200/JCO-25-00570
- 2. Burtness B, et al. "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic HNSCC (KEYNOTE-048)." The Lancet. 2019.
- 3. Taylor MH, et al. "Lenvatinib Plus Pembrolizumab in Patients With Advanced HNSCC (KEYNOTE-146)." JCO. 2020.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.